AMSTERDAM, January 8, 2013 /PRNewswire/ --
Elsevier to expand its suite of solutions to cover the entire drug discovery and development value chain by launching new life sciences solutions
Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today the acquisition of Aureus Sciences, a Paris, France based privately held company that provides databases and information tools to pharmaceutical and biotech companies.
Formed in 2002, Aureus Sciences gathers unique and high quality quantitative biological activity data for major therapeutic drug targets. This content enables researchers to identify the most promising compounds, repurpose existing compounds and identify targets with which the new compounds might interact."The acquisition of Aureus Sciences provides us with tremendous opportunities to generate more value for our customers," said Mark van Mierle, Managing Director Elsevier Pharmaceutical and Biotech Group. "With the combination of Aureus content assets and the content already available by Elsevier, we can create a valuable solution for those in need of improving speed and accuracy of lead-finding, decision-making and other key processes." The acquisition enables the combination of high quality and deeply extracted content from both companies to launch new solutions for our Pharmaceutical and Biotech customers. The first evidence of this will be seen early this year with the release of a new medicinal chemistry solution. "The integration of Aureus into Elsevier, and the consolidation of best in class content, will complement Elsevier's leadership in biomedical disciplines and strengthen our ability to offer new innovative databases to researchers in medicinal chemistry and pharmacology," said Jason Theodosiou, CEO of Aureus Sciences. "We will see many positive synergies resulting from this combination." The acquisition is effective immediately and financial terms of the transaction are not being disclosed.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV